Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
UCSF - Helen Diller Family Cancer Center, San Francisco, California Dana Farber/Harvard Cancer Center, Boston, Massachusetts South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan Icahn School of Medicine at Mt. Sinai, New York, New York South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio, Texas South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City, Utah